- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA Therapeutics Platform
Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 10,143,758. As quoted in the press release: This patent titled “Liver Specific Delivery of …
Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 10,143,758.
As quoted in the press release:
This patent titled “Liver Specific Delivery of Messenger RNA” builds on the Company’s 2009 patent filing relating to liposomal delivery of therapeutic mRNA to the liver, enhancing the Company’s current intellectual property by providing additional coverage for core delivery capabilities. This patent is owned by Translate Bio and provides protection until March, 2032.
“Since the inception of our technology, our scientists have been focused on the design and delivery of mRNA as a therapeutic and on building our intellectual property to support our discoveries,” said Ron Renaud, chief executive officer of Translate Bio. “This patent reflects the early, pioneering work of our scientists to advance the field of mRNA therapeutics with the goal of delivering innovative treatments to patients suffering from debilitating genetic diseases.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.